Back

Insights from the Castle AF: why was it positive?

3 April 2022 (18:29 - 18:41)
Organised by:
Congress Presentation Part of: Atrial fibrillation (AF) in HFrEF, HFmrEF and HFpEF: does it make any difference? Heart Failure in Atrial Fibrillation EHRA Premium Access EHRA 2022

About the speaker

Photo
Professor Nassir Marrouche

Tulane University, New Orleans (United States of America)

4 More presentations in this session

Presentation thumbnail
AF in HFrEF, HFmrEF and HFpEF: does it make any difference?
Professor R. De Boer (Rotterdam, NL)
Slides Video
Presentation thumbnail
SGLT2 blockers in AF: the best AAD ever?
Professor F. Ruschitzka (Zurich, CH)
Slides Video
Presentation thumbnail
The future of AF ablation in heart failure.
Professor D. Gupta (Liverpool, GB)
Slides Video
Presentation thumbnail
Atrial Fibrillation (AF) in HFrEF, HFmrEF and HFpEF: does it make any difference? - discussion.
Video

Access the full session

Session thumbnail
Atrial fibrillation (AF) in HFrEF, HFmrEF and HFpEF: does it make any difference?
Video

The Event

Event poster

EHRA 2022

3 April 2022 18:29 CET
You may be interested in
thumbnail
Congress Presentation
Patient selection and timing of catheter ablation for atrial fibrillation in HFrEF: is early better?
8 April 2024
thumbnail
Congress Presentation
Atrial myopathy to guide AF ablation.
4 April 2022
thumbnail
Congress Presentation
Catheter ablation in end-stage heart failure with atrial fibrillation: two-year follow-up of the CASTLE-HTx trial
30 August 2024
thumbnail
Congress Presentation
Pulmonary vein isolation should be performed on all patients with impaired left ventricular function: con
1 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources